P. Barnett

发表

Relationship Between Clinical Signs and Transmission of an Infectious Disease and the Implications for Control

S. Gubbins, M. Woolhouse, M. Chase-Topping, 2011, Science.

Foot-and-Mouth Disease Virus Replicates Only Transiently in Well-Differentiated Porcine Nasal Epithelial Cells

P. Dash, H. Takamatsu, T. Jackson, 2010, Journal of Virology.

Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review

P. Barnett, S. Cox, 2008, Veterinary research.

Experimental studies with foot-and-mouth disease virus, strain O, responsible for the 2001 epidemic in the United Kingdom.

R. Kitching, S. Alexandersen, Z. Zhang, 2002, Vaccine.

Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine.

K. McCullough, P. Barnett, N. Aggarwal, 2002, Vaccine.

Emergency vaccination of sheep against foot-and-mouth disease: protection against disease and reduction in contact transmission.

J. Salt, P. Barnett, S. Cox, 1998, Vaccine.

FMD vaccines: reflections on quality aspects for applicability in European disease control policy.

K. De Clercq, D. Mackay, P. Barnett, 2008, Transboundary and emerging diseases.

The importance of quality assurance/quality control of diagnostics to increase the confidence in global foot-and-mouth disease control.

K. De Clercq, D. Mackay, P. Barnett, 2008, Transboundary and emerging diseases.

Porcine γδ T cells: Possible roles on the innate and adaptive immune responses following virus infection

P. Dash, H. Takamatsu, P. Barnett, 2006 .

Characteristics of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion in experimentally infected cattle.

A. Bøtner, G. Belsham, N. Knowles, 2014, Veterinary microbiology.

Tumour localization using monoclonal antibodies. H. Biodistribution of A5B7/111 indium chelates

R. Buckley, J. Boden, P. Barnett, 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.

N. Knowles, D. Paton, P. Barnett, 2010, Vaccine.

Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.

R. Parkhouse, P. Barnett, A. Samuel, 1998, The Journal of general virology.

Progress in the development of DNA vaccines against foot-and-mouth disease

P. Barnett, V. Fowler, 2012, Expert review of vaccines.

Understanding foot-and-mouth disease virus transmission biology: identification of the indicators of infectiousness

M. Woolhouse, M. Chase-Topping, N. Juleff, 2013, Veterinary Research.

A comparative distribution study of 111In-labelled DTPA and TTHA monoclonal antibody conjugates in a choriocarcinoma xenograft model

R. Buckley, R. Pedley, J. Boden, 2004, European Journal of Nuclear Medicine.

Vaccine Strategic Reserves

P. Barnett, A. Füssel, 2021 .

A review of emergency foot-and-mouth disease (FMD) vaccines.

H. Carabin, P. Barnett, 2002, Vaccine.

A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease.

H. Takamatsu, L. Robinson, P. Barnett, 2012, Antiviral research.

Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost.

Yanmin Li, H. Takamatsu, P. Barnett, 2008, Vaccine.

Evaluation of a monoclonal antibody-based approach for the selection of foot-and-mouth disease (FMD) vaccine strains.

N. Knowles, D. Paton, P. Barnett, 2008, Veterinary microbiology.

Identification of a novel cell culture adaptation site on the capsid of foot-and-mouth disease virus

T. Jackson, S. Gold, N. Knowles, 2015, The Journal of general virology.

The role of small ruminants in the epidemiology and transmission of foot-and-mouth disease.

P. Barnett, S. Cox, S J Cox, 1999, Veterinary journal.

The suitability of the 'emergency' foot-and-mouth disease antigens held by the International Vaccine Bank within a global context.

P. Barnett, R. Statham, A. Samuel, 2001, Vaccine.

Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state.

P. Barnett, T. Doel, L. Williams, 1994, Vaccine.

Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines.

P. Barnett, N. Aggarwal, S. Cox, 2003, Vaccine.

Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O.

Yanmin Li, H. Takamatsu, P. Barnett, 2006, Vaccine.

A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies II: Waiting Periods After Emergency Vaccination in FMD Free Countries.

P. Barnett, T. R. Kasari, D. Geale, 2015, Transboundary and emerging diseases.

A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies I: Benefits of Higher Potency Vaccines and Associated NSP DIVA Test Systems in Post-Outbreak Surveillance.

P. Barnett, T. R. Kasari, D. Geale, 2015, Transboundary and emerging diseases.

Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV.

Y. Li, H. Takamatsu, M. Lane, 2006, Vaccine.

Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.

S. Reid, D. Paton, P. Barnett, 2006, Vaccine.

Foot-and-mouth disease marker vaccine: cattle protection with a partial VP1 G-H loop deleted virus antigen.

F. Maree, N. Knowles, P. Barnett, 2011, Vaccine.

The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease.

S. Reid, D. Paton, P. Barnett, 2005, Vaccine.

Secretory IgA as an indicator of oro-pharyngeal foot-and-mouth disease virus replication and as a tool for post vaccination surveillance.

D. Paton, P. Barnett, S. Cox, 2006, Vaccine.

Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV.

S. Reid, B. Charleston, D. Paton, 2006, Vaccine.

Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the "carrier" state in sheep.

S. Reid, P. Barnett, N. Aggarwal, 2004, Vaccine.

Interferon-γ Induced by In Vitro Re-Stimulation of CD4+ T-Cells Correlates with In Vivo FMD Vaccine Induced Protection of Cattle against Disease and Persistent Infection

D. Paton, P. Barnett, Y. Oh, 2012, PloS one.

Recovery of Viral RNA and Infectious Foot-and-Mouth Disease Virus from Positive Lateral-Flow Devices

S. Reid, D. King, P. Barnett, 2014, PloS one.

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants.

P. Barnett, T. Doel, L. Pullen, 1996, Vaccine.

Detection of antibody to the foot-and-mouth disease virus (FMDV) non-structural polyprotein 3ABC in sheep by ELISA.

D. Mackay, D. Paton, P. Barnett, 2005, Journal of virological methods.

Stratified and cryogenically stored (SACS) vaccines, a new concept in emergency foot-and-mouth disease vaccine formulation and storage.

P. Barnett, R. Statham, 2002, Vaccine.

A protective anti-peptide antibody against the immunodominant site of the A24 Cruzeiro strain of foot-and-mouth disease virus and its reactivity with other subtype viruses containing the same minimum binding sequence.

P. Barnett, T. Doel, R. Butcher, 1996, The Journal of general virology.

Immune response characteristics following emergency vaccination of pigs against foot-and-mouth disease.

K. McCullough, A. Summerfield, P. Barnett, 2005, Vaccine.

Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.

E. Rieder, D. Paton, P. Barnett, 2008, Vaccine.

Reducing animal experimentation in foot-and-mouth disease vaccine potency tests.

D. Haydon, R. Reeve, P. Barnett, 2011, Vaccine.

IL-6 production following vaccination in pigs--an additional immune response parameter for assessing FMD vaccine efficacy?

S. Gubbins, P. Barnett, S. Cox, 2011, Vaccine.

Innate immune responses following emergency vaccination against foot-and-mouth disease virus in pigs.

C. P. Carrasco, K. McCullough, P. Barnett, 2003, Vaccine.

Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission.

J. Salt, P. Barnett, P. Dani, 1998, Vaccine.

Protection against direct-contact challenge following emergency FMD vaccination of cattle and the effect on virus excretion from the oropharynx.

S. Reid, D. Paton, P. Barnett, 2005, Vaccine.

Development of an anti-cotinine vaccine to potentiate nicotine-based smoking cessation strategies.

S. Wonnacott, P. Barnett, T. Gallagher, 2007, Vaccine.

Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach.

D. Haydon, W. Vosloo, P. Barnett, 2003, Vaccine.

Interspecies Major Histocompatibility Complex-Restricted Th Cell Epitope on Foot-and-Mouth Disease Virus Capsid Protein VP4

K. McCullough, F. Sobrino, C. Chiva, 2000, Journal of virology.

The Global control of FMD-Tools, ideas and ideals – Erice, Italy 14-17 October 2008 171 CAN IN VITRO METHODS RELIABLY REPLACE EXISTING VACCINE CHALLENGE TESTS?

D. Haydon, R. Reeve, P. Barnett, 2008 .

Porcine gammadelta T cells: possible roles on the innate and adaptive immune responses following virus infection.

P. Dash, H. Takamatsu, P. Barnett, 2006, Veterinary Immunology and Immunopathology.

WITHDRAWN: Foot-and-mouth disease: How much airborne virus do animals exhale?

S. Gubbins, C. Wright, D. Paton, 2008, Veterinary journal.

Aspects of emergency vaccination against foot-and-mouth disease.

R. Kitching, A. J. Garland, P. Barnett, 2002, Comparative immunology, microbiology and infectious diseases.

The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid).

B. McGinn, D. Rowlands, F. Brown, 1989, The Journal of general virology.

Further evaluation of higher potency vaccines for early protection of cattle against FMDV direct contact challenge.

S. Reid, D. Paton, P. Barnett, 2007, Vaccine.

Foot-and-mouth disease--the vaccine.

P. Barnett, 2001, Biologist.

Importance of cell mediated immunity for protection against Foot and Mouth Disease

B. Charleston, D. Paton, P. Barnett, 2007 .